Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 12, 2024 16:05 ET | Source: 23andMe, Inc.

One of the Largest and Most Diverse Studies on Sickle Cell Trait and Blood Clots Reveals Findings That Impact All Populations

SUNNYVALE, Calif., Sept. 12, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading genetic health and biopharmaceutical company, in collaboration with lead researchers at...
September 04, 2024 09:49 ET | Source: BioAro

Biongevity Enhances Longevity Strategy with Harish Consul as Chief Venture Capital Advisor

Biongevity appoints Harish Consul as Chief Venture Capital Advisor, accelerating global growth with innovative precision health and longevity strategies.
July 25, 2024 07:30 ET | Source: 23andMe, Inc.

Twenty Lung Cancer Advocacy Organizations and 23andMe Come Together to Launch Lung Cancer Genetics Study to Help Advance Research

SUNNYVALE, Calif., July 25, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME), a leading genetic health and biopharmaceutical company, in collaboration with 20 lung cancer advocacy...
March 04, 2024 10:00 ET | Source: Baylor Genetics

Baylor Genetics to Share Scientific and Clinical Insights on AI, Precision Diagnostics, Carrier Screening and More in 11 Presentations at ACMG 2024

Researchers present abstracts and poster sessions showcasing research and clinical solutions. Joint session planned with Illumina.
January 16, 2024 03:58 ET | Source: MarketResearch.biz

Epigenetics Market Predicted to Garner USD 12.7 Billion By 2033, At CAGR 19.2% | Exclusive Report by Marketresearch.biz

New York, Jan. 16, 2024 (GLOBE NEWSWIRE) -- The epigenetics market was valued at USD 2.3 billion in 2023 with a significant growth and is projected to reach at USD 12.7 billion by 2033 with a CAGR...
January 03, 2024 10:00 ET | Source: Baylor Genetics

Baylor Genetics Accelerates Growth, Combines Clinical and Scientific Expertise with Commercial Capabilities to Meet Increased Needs of Patients, Providers and Partners

Company Expands Test Offerings, Lab Technology, and Customer-Centric Tools Rapid Comprehensive Whole Genome and Exome Sequencing, Disease-Specific Panels and Customizable Solutions Advance Diagnoses...
November 28, 2023 07:42 ET | Source: Optimi Health Corp.

Optimi Health Achieves Genetics Milestone and Completes Psilocybin Extract Validation and Stability Testing

VANCOUVER, British Columbia, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN), a leading end-to-end drug researcher and formulator licensed by Health...
November 06, 2023 12:00 ET | Source: NeuroQure

Revolutionizing Care: NeuroQure’s Groundbreaking Path to Treating Genetic Intellectual Disabilities

IRVINE, Calif., Nov. 06, 2023 (GLOBE NEWSWIRE) -- NeuroQure has embarked on a transformative journey aimed at revolutionizing the treatment landscape for Fragile X Syndrome and Autism Spectrum...
October 10, 2023 09:30 ET | Source: SOHM, Inc.

SOHM Collaborates with University of Arizona Center for Innovation to Advance ABBIE, a Groundbreaking Non-Viral Gene-Editing Technology

CHINO HILLS, Calif., Oct. 10, 2023 (GLOBE NEWSWIRE) -- via IBN -- SOHM, Inc. (OTC PINK: SHMN), a pharmaceutical, nutraceutical and cosmeceutical company that manufactures and markets generic drugs...
September 21, 2023 07:00 ET | Source: Synlogic, Inc.

Synlogic to Participate in Chardan’s Genetic Medicines Conference

CAMBRIDGE, Mass., Sept. 21, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company advancing novel, oral, non-systemically absorbed biotherapeutics to...